Last reviewed · How we verify
Dl-Prenylamine (PRENYLAMINE)
Prenylamine, a marketed drug by an unspecified company, operates by blocking sodium channels in the brain to reduce abnormal electrical activity, with a key composition patent expiring in 2028. Its primary competitive advantage lies in its distinct mechanism of action, setting it apart from same-class drugs like nesiritide and vericiguat. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | PRENYLAMINE |
|---|---|
| Drug class | prenylamine |
| Target | Sodium channel alpha subunits; brain (Types I, II, III), Calmodulin, Voltage-gated L-type calcium channel |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |